Abstract

Objective To investigate the role of receptor for advanced glycation end-products nuclear factor-κB (RAGE-NF-κB) signaling pathway in the renal ischemia reperfusion injury in rats. Methods The rats of acute ischemia reperfusion injury (RIRI) model was induced by bilateral clamping the renal artery and vein for 45 minutes followed by reperfusion. Fifty-four SD rats were divided into 3 groups by complete randomization method (18 cases in each group). (1) Sham surgery group (Intraperitoneal injection of 60 mg/kg saline solution, S-group); (2) Model group; (IR) (3) Alpha lipoic acid pretreatment group (ALA 60 mg/kg intraperitoneal injection of 30 min before reperfusion ALA-group). Observed the general situation in rats, animals were killed in different reperfusion time (1, 6, 12 h). Renal patho-histological changes were examined by hematoxylin and eosin (HE) staining; The level of blood urea nitrogen was measured by Jaffe’s assay; The expression of interleukin (IL)-6 and tumor necrosis factor-α (TNF-α) were measured by enzyme linked immunosorbent assay (ELISA); RAGE protein and NF-κB protein were determin-ed by Western blotting; The expression of renal RAGE mRNA, NF-κB mRNA were detected by real-time quantitative polymerase chain reaction (Real-time PCR). Results As compared with the sham operation group, the blood levels of Scr in IR group were significantly elevated (F=4.867, P=0.013); the expression of renal RAGE protein and RAGE mRNA, NF-κB protein RAGE mRNA in IR rats were increased significantly. Compared with IR group, the expression of Scr, TNF-α, IL-6, RAGE protein and RAGE mRNA, NF-κB protein RAGEs mRNA in ALA group rats were decreased significantly. Conclusion RAGE-NF-κB signaling pathway regulates the enal ischemia reperfusio-ninjury rats. ALA has a protective effect on RIRI. Key words: Ischemia reperfusion injury; Receptor for advanced glycation end -products; Nuclear factor-κB; Renal; Rat; Alpha lipoic acid

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.